About MetaStat, Inc.
MetaStat, Inc. (OTCQB: MTST) is a biotechnology company focused on the development and commercialization of diagnostic tests prognostic for risk of cancer metastasis, companion diagnostics to predict drug response, and anti-metastatic drugs. Our driver-based platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease in epithelial-based solid tumors.
Our product development strategy is based on identifying patients most at risk for cancer metastasis and targeting the underlying mechanisms that drive the metastatic cascade. Unlike most oncology therapeutics that kill cancer cells directly or inhibit cancer cell proliferation, we focus on preventing aggressive tumors from spreading. This is particularly relevant as most cancer deaths are caused by aggressive tumors that spread throughout the body and not due to growth of the primary tumor.
|
|
|
1-10 employees
View all MetaStat, Inc. employees
|
|
Biotechnology Research
|
|
None
|
MetaStat, Inc. Alternatives
Frequently Asked Questions about MetaStat, Inc.
Douglas Hamilton is the CEO of MetaStat, Inc.. To contact Douglas Hamilton email at [email protected].
The decision makers in MetaStat, Inc. are Douglas Hamilton, Oscar Bronsther, etc. Click to Find MetaStat, Inc. decision makers emails.
MetaStat, Inc. Staff Directory
Search MetaStat, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
